[1] Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;

379(9811):165-80. [DOI:10.1016/S0140-6736(11)60178-5]

[PMID]

[2] Warady BA, Chadha V. Chronic kidney disease in children:

the global perspective. Pediatr Nephrol. 2007; 22(12):1999-

2009. [DOI:10.1007/s00467-006-0410-1] [PMID]

[3] Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya

T, Gejyo F, et al. Possible involvement of circulating fibroblast

growth factor 23 in the development of secondary hyperparathyroidism

associated with renal insufficiency. Am J Kidney

Dis. 2004; 44(2):250-6. [DOI:10.1053/j.ajkd.2004.04.029]

[PMID]

[4] Komaba H, Fukagawa M. Pathogenesis of CKD-MBD. Bone.

2009; 45:44. [Link]

[5] Kidney Disease: Improving Global Outcomes (KDIGO)

CKD-MBD Update Work Group. KDIGO 2017 clinical practice

guideline update for the diagnosis, evaluation, prevention,

and treatment of chronic kidney disease-mineral and

bone disorder (CKD-MBD). Kidney Int Suppl. 2017; 7(1):1-59.

[DOI:10.1016/j.kisu.2017.04.001] [PMID]

[6] Rees L, Mak RH. Nutrition and growth in children with

chronic kidney disease. Nat Rev Nephrol. 2011; 7(11):615-23.

[DOI:10.1038/nrneph.2011.137] [PMID]

[7] Dasgupta I, Shroff R, Bennett-Jones D, McVeigh G; NICE

Hyperphosphataemia Guideline Development Group. Management

of hyperphosphataemia in chronic kidney disease:

summary of National Institute for Health and Clinical Excellence

(NICE) guideline. Nephron Clin Pract. 2013; 124(1-2):1-

9. [DOI:10.1159/000354711] [PMID]

[8] Mak RH, Iyengar A, Lai WM, McAlister L, Oliveira EA, Xu H,

et al. Nutrition in children with chronic kidney disease: How

to thrive? J Ren Nutr. 2023; 33(6S):S49-S55. [DOI:10.1053/j.

jrn.2023.07.006] [PMID]

[9] Wesseling-Perry K, Salusky IB. Chronic kidney disease:

Mineral and bone disorder in children. Semin Nephrol. 2013;

33(2):169-79. [DOI:10.1016/j.semnephrol.2012.12.017] [PMID]

[10] Mitsnefes MM. Cardiovascular disease in children with

chronic kidney disease. J Am Soc Nephrol. 2012; 23(4):578-85.

[DOI:10.1681/ASN.2011111115] [PMID]

[11] KDOQI Work Group. KDOQI clinical practice guideline

for nutrition in children with CKD: 2008 update. Executive

summary. Am J Kidney Dis. 2009; 53(3 Suppl 2):S11-04.

[DOI:10.1053/j.ajkd.2008.11.017] [PMID]

[12] Mac Way F, Lessard M, Lafage-Proust MH. Pathophysiology

of chronic kidney disease-mineral and bone disorder.

Joint Bone Spine. 2012; 79(6):544-9. [DOI:10.1016/j.jbspin.

2012.09.014] [PMID]

[13] Hruska KA, Seifert M, Sugatani T. Pathophysiology of

the chronic kidney disease-mineral bone disorder. Curr

Opin Nephrol Hypertens. 2015; 24(4):303-9. [DOI:10.1038/

bonekey.2013.231]

[14] Lanske B, Densmore M, Razzaque MS. Regulation of phosphate

metabolism by FGF23. In: Lanske B, Densmore M,

Razzaque MS, editors. Translational endocrinology of bone.

Cambridge: Academic Press; 2013. [Link]

[15] Habas E Sr, Eledrisi M, Khan F, Elzouki AY. Secondary

hyperparathyroidism in chronic kidney disease: Pathophysiology

and management. Cureus. 2021; 13(7):e16388.

[DOI:10.7759/cureus.16388] [PMID]

[16] Wesseling-Perry K, Salusky IB. Chronic Kidney Disease

Mineral and Bone Disorder In: Jameson JM, De Groot LJ,

editors. Endocrinology (sixth edition). Amsterdam: Elsevier;

2011. [DOI:10.1016/B978-1-4160-5583-9.00069-1]

[17] Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-

Perry K. The consequences of chronic kidney disease on bone

metabolism and growth in children. Nephrol Dial Transplant.

2012; 27(8):3063-71. [DOI:10.1093/ndt/gfs299] [PMID]

[18] Fernández-Iglesias Á, López JM, Santos F. Growth plate

alterations in chronic kidney disease. Pediatr Nephrol. 2020;

35(3):367-74. [DOI:10.1007/s00467-018-4160-7] [PMID]

[19] Yang Y, Yang K, Xiong Y, He Y, Zhou Y, Hayden MR.

Phosphate toxicity and vascular calcification in chronic kidney

disease: A closer look utilizing transmission electron microscopy.

Curr Protein Pept Sci. 2023; 24(8):621-39. [DOI:10.21

74/1389203724666230726151019] [PMID]

[20] Rroji M, Figurek A, Viggiano D, Capasso G, Spasovski G.

Phosphate in the context of cognitive impairment and other

neurological disorders occurrence in chronic kidney disease.

Int J Mol Sci. 2022; 23(13):7362. [DOI:10.3390/ijms23137362]

[PMID]

[21] Bistarakis L, Voskaki I, Lambadaridis J, Sereti H, Sbyrakis

S. Renal handling of phosphate in the first six months

of life. Arch Dis Child. 1986; 61(7):677-81. [DOI:10.1136/

adc.61.7.677] [PMID]

[22] Lalayiannis AD, Soeiro EMD, Moysés RMA, Shroff R.

Chronic kidney disease mineral bone disorder in childhood

and young adulthood: A 'growing' understanding. Pediatr

Nephrol. 2024; 39(3):723-39. [DOI:10.1007/s00467-023-06109-

3] [PMID]

[23] Sanchez CP. Mineral metabolism and bone abnormalities

in children with chronic renal failure. Rev Endocr Metab

Disord. 2008; 9(2):131-7. [DOI:10.1007/s11154-007-9071-z]

[PMID]

[24] Wesseling-Perry K, Salusky IB. Chronic kidney disease:

Mineral and bone disorder in children. Semin Nephrol. 2013;

33(2):169-79. [DOI:10.1016/j.semnephrol.2012.12.017]

[25] Chanchlani R, Nemer P, Sinha R, Nemer L, Krishnappa V,

Sochett E, et al. An overview of rickets in children. Kidney

Int Rep. 2020; 5(7):980-90. [DOI:10.1016/j.ekir.2020.03.025]

[PMID]

[26] Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky

A, Portale AA, et al. Fracture burden and risk factors in childhood

CKD: Results from the CKiD cohort study. J Am Soc

Nephrol. 2016; 27(2):543-50. [DOI:10.1681/ASN.2015020152]

[PMID]

[27] Silverstein DM. Growth and nutrition in pediatric chronic

kidney disease. Front Pediatr. 2018; 6:205. [PMID]

[28] Schaefer F. Endocrine and growth abnormalities in children

with chronic renal disease. In: Avner E, Harmon W,

Niaudet P, Yoshikawa N, Emma F, Goldstein S, editors. Pediatric

nephrology. Berlin: Springer; 2015. [Link]

[29] Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification

in patients with end-stage renal disease: A century-

old phenomenon. Kidney Int Suppl. 2002; (82):S73-80.

[DOI:10.1046/j.1523-1755.62.s82.15.x] [PMID]

[30] Zanoli L, Lentini P, Briet M, Castellino P, House AA,

London GM, et al. Arterial stiffness in the heart disease of

CKD. J Am Soc Nephrol. 2019; 30(6):918-28. [DOI:10.1681/

ASN.2019020117] [PMID]

[31] Querfeld U, Schaefer F. Cardiovascular risk factors in

children on dialysis: an update. Pediatr Nephrol. 2020

Jan;35(1):41-57. [DOI:10.1007/s00467-018-4125-x] [PMID]

[32] Hooper SR, Gerson AC, Butler RW, Gipson DS, Mendley

SR, Lande MB, et al. Neurocognitive functioning of children

and adolescents with mild-to-moderate chronic kidney disease.

Clin J Am Soc Nephrol. 2011; 6(8):1824-30. [DOI:10.2215/

CJN.09751110] [PMID]

[33] Harshman LA, Hooper SR. The brain in pediatric chronic

kidney disease-the intersection of cognition, neuroimaging,

and clinical biomarkers. Pediatr Nephrol. 2020; 35(12):2221-9.

[DOI:10.1007/s00467-019-04417-1] [PMID]

[34] Amirkashani D, Hooman N, Shahidzadeh M. Delayed

puberty and its association with hormonal changes in children

with chronic renal insufficiency. Acta Med Iran. 2022;

60(4):243-8. [DOI:10.18502/acta.v60i4.9269]

[35] Díaz-González de Ferris ME, Pierce CB, Gipson DS, Furth

SL, Warady BA, et al. Health-related quality of life in children

with chronic kidney disease is affected by the number of medications.

Pediatr Nephrol. 2021; 36(5):130710. [DOI:10.1007/

s00467-021-04919-x] [PMID]

[36] Jansz TT, Go MHY, Hartkamp NS, Stöger JL, Celeng

C, Leiner T, et al. Coronary artery calcification as a marker

for coronary artery stenosis: Comparing kidney failure to

the general population. Kidney Med. 2021; 3(3):386-394.e1.

[DOI:10.1016/j.xkme.2021.01.010] [PMID]

[37] van 't Klooster CC, Nathoe HM, Hjortnaes J, Bots ML, Isgum

I, Lessmann N, et al. Multifocal cardiovascular calcification

in patients with established cardiovascular disease;

prevalence, risk factors, and relation with recurrent cardiovascular

disease. Int J Cardiol Heart Vasc. 2020; 27:100499.

[DOI:10.1016/j.ijcha.2020.100499] [PMID]

[38] Edmonston D, Isakova T, Dember LM, Waymyers S, Andersen

D, Chan KE, et al. Higher versus lower phosphate

targets for patients undergoing in-center hemodialysis:

A randomized controlled trial. J Am Soc Nephrol. 2025;

36(12):2445-55. [DOI:10.1681/ASN.0000000765] [PMID]

[39] Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans

PI. Phosphate binders in patients with chronic kidney

disease. Aust Prescr. 2017; 40(1):10-14. [DOI:10.18773/austprescr.

2017.002] [PMID]

[40] Patel L, Bernard LM, Elder GJ. Sevelamer versus calciumbased

binders for treatment of hyperphosphatemia in CKD:

A meta-analysis of randomized controlled trials. Clin J Am

Soc Nephrol. 2016; 11(2):232-44. [DOI:10.2215/CJN.06800615]

[PMID]

[41] Locatelli F, Del Vecchio L. Iron-based phosphate binders: A

paradigm shift in the treatment of hyperphosphatemic anemic

CKD patients? J Nephrol. 2017; 30(6):755-65. [DOI:10.1007/

s40620-017-0421-y] [PMID]

[42] Corsello A, Spolidoro GCI, Milani GP, Agostoni C. Vitamin

D in pediatric age: Current evidence, recommendations,

and misunderstandings. Front Med. 2023; 10:1107855.

[DOI:10.3389/fmed.2023.1107855] [PMID]

[43] Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox

J, Moylan K. Cinacalcet is efficacious in pediatric dialysis patients.

Pediatr Nephrol. 2008; 23(10):1817-22. [DOI:10.1007/

s00467-007-0742-5] [PMID]

[44] Bernardor J, Flammier S, Salles JP, Amouroux C, Castanet

M, Lienhardt A, et al. Off-label use of cinacalcet in pediatric

primary hyperparathyroidism: A French multicenter

experience. Front Pediatr. 2022; 10:926986. [DOI:10.3389/

fped.2022.926986] [PMID]

[45] Umeukeje EM, Mixon AS, Cavanaugh KL. Phosphate-control

adherence in hemodialysis patients: current perspectives.

Patient Prefer Adherence. 2018; 12:1175-91. [DOI:10.2147/

PPA.S145648] [PMID]

[46] Wish JB. Tenapanor as add-on treatment for hyperphosphatemia

in dialysis patients: Enough bang for the

buck? Kidney Int Rep. 2023; 8(11):2194-7. [DOI:10.1016/j.

ekir.2023.10.001] [PMID]

[47] Holick MF. High prevalence of vitamin D inadequacy and

implications for health. Mayo Clin Proc. 2006; 81(3):353-73.

[DOI:10.4065/81.3.353] [PMID]

[48] Zmijewski MA. Vitamin D and human health. Int J Mol Sci.

2019; 20(1):145. [DOI:10.3390/ijms20010145] [PMID]

[49] Wesseling-Perry K. Bone disease in pediatric chronic

kidney disease. Pediatr Nephrol. 2013; 28(4):569-76.

[DOI:10.1007/s00467-012-2324-4] [PMID]

[50] Reddy P, Edwards LR. Magnesium supplementation

in vitamin D deficiency. Am J Ther. 2019; 26(1):e124-32.

[DOI:10.1097/MJT.0000000000000538] [PMID]

[51] Saran R, Li Y, Robinson B. US renal data system 2015,

annual data report: Epidemiology of kidney disease in the

United States. Am J Kidney Dis. 2016; 67(3):Svii,S1-S305.

[DOI:10.1053/j.ajkd.2015.12.015]

[52] Akchurin OM, Schneider MF, Mulqueen L, Brooks ER,

Langman CB, Greenbaum LA, et al. Medication adherence

and growth in children with CKD. Clin J Am Soc Nephrol.

2014; 9(9):1519-25. [DOI:10.2215/CJN.01150114] [PMID]

[53] Narasaki Y, Rhee CM. Dietary therapy for managing hyperphosphatemia.

Clin J Am Soc Nephrol. 2020; 16(1):9-11.

[DOI:10.2215/CJN.18171120] [PMID]

[54] Trivedi H, Szabo A, Zhao S, Cantor T, Raff H. Circadian

variation of mineral and bone parameters in end-stage renal

disease. J Nephrol. 2015; 28(3):351-9. [DOI:10.1007/s40620-

014-0124-6] [PMID]

[55] Broman M, Wilsson AMJ, Hansson F, Klarin B. Analysis

of hypo- and hyperphosphatemia in an intensive care unit

cohort. Anesth Analg. 2017; 124(6):1897-905. [DOI:10.1213/

ANE.0000000000002077] [PMID]

[56] Beto J, Bhatt N, Gerbeling T, Patel C, Drayer D. Overview

of the 2017 KDIGO CKD-MBD update: Practice implications

for adult hemodialysis patients. J Ren Nutr. 2019; 29(1):2-15.

[DOI:10.1053/j.jrn.2018.05.006] [PMID]

[57] Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism.

Endocrinol Metab Clin North Am. 2018; 47(4):865-88.

[DOI:10.1016/j.ecl.2018.07.011] [PMID]

[58] Gerson AC, Butler R, Moxey-Mims M, Wentz A, Shinnar

S, Lande MB, et al. Neurocognitive outcomes in children with

chronic kidney disease: Current findings and contemporary

endeavors. Ment Retard Dev Disabil Res Rev. 2006; 12(3):208-

15. [DOI:10.1002/mrdd.20116] [PMID]

[59] Karavetian M, Rizk R. Patient education for hyperphosphatemia

management: Improving outcomes while

decreasing costs? Kidney Res Clin Pract. 2018; 37(1):4-7.

[DOI:10.23876/j.krcp.2018.37.1.4] [PMID]

[60] Leaf DE, Wolf M. A physiologic-based approach to the

evaluation of a patient with hyperphosphatemia. Am J Kidney

Dis. 2013; 61(2):330-6. [DOI:10.1053/j.ajkd.2012.06.026]

[PMID]

[61] Miyagawa A, Tatsumi S, Takahama W, Fujii O, Nagamoto

K, Kinoshita E, et al. The sodium phosphate cotransporter

family and nicotinamide phosphoribosyltransferase contribute

to the daily oscillation of plasma inorganic phosphate concentration.

Kidney Int. 2018; 93(5):1073-85. [DOI:10.1016/j.

kint.2017.11.022] [PMID]